Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan) Commenting Expert: Emiel Rutgers, Netherlands Cancer Institute, Amsterdam Angel Rod
Scientific Editors:George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan)Commenting Expert:Emiel Rutgers, Netherlands Cancer Institute, Amsterdam
Angel Rodriguez
In this edition:
1. Lapatinib: Targets Breast Cancer Stem Cells?
Angel Rodriguez, Baylor College, Houston
2. No Help Adding Neoadjuvant Capecitabine
Gunter von Minckwitz, German Breast Group, Neu-Isenberg
3. MRI Aids Breast Surgery Planning
David Martinez-Cecilia, University Hospital Reina Sofia, Córdoba
4. Aromatase Inhibitors: No Extra Heart Risk
Alain Monnier, Centre Hospitalier de Belfort, Montbéliard
5. NAB Paclitaxel For Metastatic Breast Cancer?
William Gradishar, Northwestern University, Chicago
Peter Goodwin and Sara Freeman interview conference speakers in Berlin regarding lapatinib’s apparent effect on breast cancer “stem cells”; the lack of additional benefit from adding capecitabine to standard neoadjuvant chemotherapy; evidence that MRI improves surgical planning for breast cancer; news that aromatase inhibitors do not add to cardiovascular risk when used in adjuvant therapy instead of tamoxifen; and (from a satellite symposium) an assessment of the role of nanoparticle albumin-bound paclitaxel in therapy for metastatic breast cancer.
Tags
Related Episodes
Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”
Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome” An interview with: Hassan Mohammed Abushukair MD, Post-Doctoral Researcher, Oklahoma Univer
Eileen M O'Reilly MD; ASCO 2026: RAS G12 Targeting Drug Daraxonrasib Doubles Survival with Pancreas Cancer in Phase 3 RASolute 302 Study
Standing ovation at ASCO for RASolute 302 Study
Matteo Lambertini MD PhD; San Antonio Breast Cancer Symposium: ALTTO Trial Shows Adjuvant Aromatase Inhibitors Outperform Tamoxifen in Patients with ER-Positive, HER2-Positive Early Breast Cancer
Matteo Lambertini MD PhD discusses new findings from the ALTTO trial at the 2025 San Antonio Breast Cancer Symposium. The long-term analysis reveals that adjuvant aromatase inhibitors lead to superior outcomes, including improved disease-free survival and time to distant recurrence, compared to tamoxifen or other SERMs.